Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma

Jesüs G. Berdeja, Richard J Jones, Marianna L. Zahurak, Steven Piantadosi, Ross A. Abrams, Michael J Borowitz, Georgia Boyce Vogelsang, Stephen J. Noga, Richard F Ambinder, Ian W. Flinn

Research output: Contribution to journalArticle

Abstract

Purpose: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). Patients and Methods: Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%), or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation. Results: The incidence of acute GVHD grade>2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95% confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46% for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease and

Original languageEnglish (US)
Pages (from-to)561-567
Number of pages7
JournalBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Volume7
Issue number10
StatePublished - 2001

Fingerprint

Mantle-Cell Lymphoma
Homologous Transplantation
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Transplantation
Mortality
Whole-Body Irradiation
Incidence
B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Disease-Free Survival
Siblings
Confidence Intervals
T-Lymphocytes
Transplants
Survival

Keywords

  • AlloBMT
  • Chronic lymphocytic leukemia
  • Event-free survival
  • Follicular lymphoma
  • Graft-versus-lymphoma effect
  • Mantle cell lymphoma
  • Transplantation-related morbidity

ASJC Scopus subject areas

  • Transplantation
  • Medicine(all)

Cite this

@article{86e0bafc312e43609cc9bc6eb94a7d00,
title = "Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma",
abstract = "Purpose: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). Patients and Methods: Thirty-five patients with low-grade lymphoma (48{\%}), chronic lymphocytic leukemia (26{\%}), or MCL (26{\%}) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31{\%} were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation. Results: The incidence of acute GVHD grade>2 was 6{\%} and of grades 1 to 2 was 37{\%}. The incidence of chronic GVHD was 6{\%}. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50{\%} (95{\%} confidence interval [CI], 33{\%}-66{\%}). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46{\%} for all patients. The TRM was 86{\%} for patients with resistant disease and 14{\%} for patients with sensitive disease and",
keywords = "AlloBMT, Chronic lymphocytic leukemia, Event-free survival, Follicular lymphoma, Graft-versus-lymphoma effect, Mantle cell lymphoma, Transplantation-related morbidity",
author = "Berdeja, {Jes{\"u}s G.} and Jones, {Richard J} and Zahurak, {Marianna L.} and Steven Piantadosi and Abrams, {Ross A.} and Borowitz, {Michael J} and Vogelsang, {Georgia Boyce} and Noga, {Stephen J.} and Ambinder, {Richard F} and Flinn, {Ian W.}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "561--567",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma

AU - Berdeja, Jesüs G.

AU - Jones, Richard J

AU - Zahurak, Marianna L.

AU - Piantadosi, Steven

AU - Abrams, Ross A.

AU - Borowitz, Michael J

AU - Vogelsang, Georgia Boyce

AU - Noga, Stephen J.

AU - Ambinder, Richard F

AU - Flinn, Ian W.

PY - 2001

Y1 - 2001

N2 - Purpose: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). Patients and Methods: Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%), or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation. Results: The incidence of acute GVHD grade>2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95% confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46% for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease and

AB - Purpose: To report survival outcomes of allogeneic BMT in patients with low-grade lymphoma or mantle cell lymphoma (MCL). Patients and Methods: Thirty-five patients with low-grade lymphoma (48%), chronic lymphocytic leukemia (26%), or MCL (26%) underwent myeloablative allogeneic BMT from HLA-identical siblings at the Johns Hopkins Oncology Center. Patients had a median age of 46 years, a median of 2 prior treatments, and 31% were in complete remission at the time of transplantation. The preparative regimen was cyclophosphamide/total body irradiation for most patients. All grafts were T-cell depleted by counter flow centrifugal elutriation with CD34+ augmentation. Results: The incidence of acute GVHD grade>2 was 6% and of grades 1 to 2 was 37%. The incidence of chronic GVHD was 6%. The median follow-up time was 25 months. The rate of event-free survival (EFS) was 50% (95% confidence interval [CI], 33%-66%). Only 1 patient relapsed. The transplantation-related mortality (TRM) was 46% for all patients. The TRM was 86% for patients with resistant disease and 14% for patients with sensitive disease and

KW - AlloBMT

KW - Chronic lymphocytic leukemia

KW - Event-free survival

KW - Follicular lymphoma

KW - Graft-versus-lymphoma effect

KW - Mantle cell lymphoma

KW - Transplantation-related morbidity

UR - http://www.scopus.com/inward/record.url?scp=0035204544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035204544&partnerID=8YFLogxK

M3 - Article

C2 - 11760088

AN - SCOPUS:0035204544

VL - 7

SP - 561

EP - 567

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 10

ER -